Precision Medicine in Oncology®

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Vebreltinib demonstrated preliminary activity in patients with non–central nervous system solid tumors harboring MET fusions.

Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.

Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

The FDA has granted de novo marketing authorization to the PGDx elio plasma focus Dx pan–solid tumor liquid biopsy test.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.